# Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia

> **NCT00330382** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 325 (actual)

## Conditions studied

- Lip and Oral Cavity Cancer
- Oral Leukoplakia
- Oropharyngeal Cancer
- Tongue Cancer

## Interventions

- **DRUG:** Bowman-Birk inhibitor concentrate
- **OTHER:** placebo
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00330382
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-01
- **Primary completion:** 2010-07
- **Final completion:** 2013-05
- **Target enrollment:** 325 (ACTUAL)
- **Last updated:** 2014-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00330382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00330382, "Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00330382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*